Mineralocorticoid receptor suppresses cancer progression and the Warburg effect by modulating the miR‐338‐3p‐PKLR axis in hepatocellular carcinoma

Huizhen Nie, Jun Li, Xiao‐Mei Yang, Qing‐Zhen Cao, Ming‐Xuan Feng, Feng Xue, Lin Wei, Wenxin Qin, Jianren Gu, Qiang Xia, Zhi‐Gang Zhang – 16 June 2015 – Hormones and their corresponding receptors are vital in controlling metabolism under normal physiologic and pathologic conditions, but less is known about their roles in the metabolism of cancer.

The corrected donor age for hepatitis C virus–infected liver transplant recipients

Melisa Dirchwolf, Jennifer L. Dodge, Jane Gralla, Kiran M. Bambha, Trevor Nydam, Kenneth W. Hung, Hugo R. Rosen, Sandy Feng, Norah A. Terrault, Scott W. Biggins – 13 June 2015 – Donor age has become the dominant donor factor used to predict graft failure (GF) after liver transplantation (LT) in hepatitis C virus (HCV) recipients. The purpose of this study was to develop and validate a model of corrected donor age (CDA) for HCV LT recipients that transforms the risk of other donor factors into the scale of donor age.

Transarterial chemoembolization with drug‐eluting beads is effective for the maintenance of the Milan‐in status in patients with a small hepatocellular carcinoma

Matteo Angelo Manini, Angelo Sangiovanni, Laura Martinetti, Davide Viganò, Vincenzo La Mura, Alessio Aghemo, Massimo Iavarone, Silvia Crespi, Antonio Nicolini, Massimo Colombo – 13 June 2015 – Transarterial chemoembolization (TACE) is the standard of care for the treatment of patients with an intermediate (Barcelona Clinic Liver Cancer [BCLC] B) hepatocellular carcinoma and to bridge patients with an early cancer to liver transplantation (LT). We explored the efficacy of TACE with drug‐eluting beads (DEB) in BCLC A patients.

Liver transplantation for alveolar echinococcosis in an endemic region

Bulent Aydinli, Gurkan Ozturk, Sukru Arslan, Mecit Kantarci, Onder Tan, Ali Ahıskalioglu, Kemalettin Özden, Abdurrahim Colak – 13 June 2015 – Alveolar echinococcosis (AE) is a chronic disease caused by ingestion of the eggs of the parasitic cestode Echinococcosis multilocularis (EM). In severe cases, liver transplantation (LT) may represent the only possibility of survival and cure. Patients undergoing LT associated with hepatic AE at our institution between April 2011 and October 2014 were investigated retrospectively.

Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis

Bashar A. Aqel, Surakit Pungpapong, Michael Leise, K. Tuesday Werner, Amy E. Chervenak, Kymberly D. Watt, Jennifer L. Murphy, Kristen Ryland, Andrew P. Keaveny, Ryan McLemore, Hugo E. Vargas – 11 June 2015 – Interferon (IFN)‐free regimens are needed to treat hepatitis C virus (HCV) infection. Combined simeprevir (SMV) and sofosbuvir (SOF) with or without ribavirin (RBV) results in high sustained virological response (SVR) rates along with minimal adverse events (AEs) in patients with hepatitis C genotype 1 (HCV GT1).

Apolipoprotein E and protection against hepatitis E viral infection in American non‐Hispanic blacks

Lyna Zhang, Ajay Yesupriya, Man‐Huei Chang, Eyasu Teshale, Chong‐Gee Teo – 11 June 2015 – Hepatitis E viral (HEV) infection imposes a heavy health burden worldwide and is common in the United States. Previous investigations of risks addressed environmental and host behavioral/lifestyle factors, but host genetic factors have not been examined.

Specific hepatic delivery of procollagen α1(I) small interfering RNA in lipid‐like nanoparticles resolves liver fibrosis

Carolina Jiménez Calvente, Alfica Sehgal, Yury Popov, Yong Ook Kim, Victor Zevallos, Ugur Sahin, Mustafa Diken, Detlef Schuppan – 10 June 2015 – Fibrosis accompanies the wound‐healing response to chronic liver injury and is characterized by excessive hepatic collagen accumulation dominated by collagen type I. Fibrosis often progresses to cirrhosis.

Low, rather than high, body mass index confers increased risk for post‐liver transplant death and graft loss: Risk modulated by model for end‐stage liver disease

Kiran M. Bambha, Jennifer L. Dodge, Jane Gralla, David Sprague, Scott W. Biggins – 10 June 2015 – With increasing attention being paid to optimizing patient outcomes, it has been proposed that liver transplantation (LT) for individuals with elevated body mass index (BMI) values and high Model for End‐Stage Liver Disease (MELD) scores may adversely affect post‐LT outcomes. We investigated the impact of BMI on post‐LT outcomes in the context of MELD at LT.

Subscribe to